Opinion: Insulin is increasingly affordable in the U.S. What about the rest of the world?
Insulin prices have started to come down in the U.S. How can we ensure people around the world have the same access?
In March, Eli Lilly, Novo Nordisk, and Sanofi — the world’s three largest insulin manufacturers — committed to reducing the U.S. list price of insulin, a drug that millions of people require to live.
Following two decades of sharp increases for consumers, the companies vowed to cut insulin prices for some insulins by at least 70%, meaning many people could see their insulin costs capped at $35 a month in the near future. (Sanofi and NovoNordisk will lower their prices as of January 2024; Lilly reduced it to $35 per month in March 2023.) While pharmacy benefit managers and the rebates paid to them by pharmaceutical companies will continue to drive up costs for patients in the U.S., competition on the horizon could help push down prices.
What's Your Reaction?
